Background: The epidemiology of respiratory viruses and their potential clinical impact
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Most respiratory tract infections acquired in the community are of viral etiology. In healthy adults, the disease is generally self-limited and restricted to the upper respiratory tract.
However, respiratory viruses cause also lower respiratory tract illnesses and even the socalled "common cold" viruses like rhino-and coronavirus can infect the lower respiratory airways [1] [2] [3] [4] . These viral infections are well known to promote complications such as bacterial infections or an exacerbation of a pre-existing, chronic lung disease such as asthma 5 .
Lower respiratory tract infections are among the most frequent causes of hospitalisation and although a significant number of cases are presumably linked to an initial viral infection acquired in the community, the viral etiology is rarely evidenced [6] [7] [8] . This is mainly related to the complexity and the costs of nucleic acid detection procedures, as well as the need for appropriate lower respiratory tract specimens 9 . In particular, the role of recently discovered viruses such as human metapneumovirus (HMpV), coronavirus NL 63 (HCoV-NL63) and HKU1 (HCoV-HKUI), as well as bocavirus, has not yet been completely assessed in the hospital setting [10] [11] [12] [13] .
In this study, we screened patients who underwent a bronchoalveolar lavage (BAL)
procedure by using sensitive nucleic acid detection assays targeting 17 different viruses to assess the potential impact of respiratory virus in hospitalised subjects with lower respiratory tract disease. By definition, this investigation in hospitalized patients will select a population at high risk for complications such as transplant recipients, immunocompromised hosts, or those with co-morbidities and chronic lung diseases. If respiratory viruses do play any significant role, this needs to be assessed first in this at-risk population.
METHODS

Study population and procedures
We conducted a hospital-based prospective cohort study in 299 patients over a 27-month period. All patients who underwent a BAL were eligible, irrespective of the reason/s leading to the procedure. The study was conducted at the University Hospitals of Geneva (Geneva, Switzerland) and included also lung transplant recipients at the University Hospital of Lausanne (Lausanne, Switzerland) which is 60 kilometres from Geneva and an integral part of our transplantation network.
Bronchoscopy was performed by pulmonary physicians based on guidelines which recommend a BAL procedure for immunocompromised hosts with persistent chest X-ray infiltrate and/or respiratory symptoms (cough with or without sputum, dyspnoea exacerbation, chest x-ray infiltrates, unexplained hypoxemia) despite broad-spectrum antibiotic treatment;
HIV-positive patients with low CD4 cell count and a suspected pulmonary opportunistic infection; cases of suspected pulmonary tuberculosis and negative sputum analysis; diffuse persistent interstitial infiltrates of unknown origin; exacerbation of respiratory symptoms in patients with chronic interstitial diseases; or nosocomial pneumonia (including intubated patients) without response to broad-spectrum antibiotic therapy. As the indication for the BAL procedure in lung transplant recipients ranged from routine surveillance to respiratory signs and symptoms with or without abnormal radiologic findings, these patients could have several BALs during the study follow-up period. Patients suspected of having primary lung cancer are submitted to bronchial brushing but not to BAL.
BAL was performed following a standardised protocol (technique, sampling and procedure): 30-50 ml of sterile saline solution was instilled two to three times into the distal bronchial tree, either at the site of the radiographic abnormality or in the middle lobe in the absence of radiographic abnormalities.
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The study was approved by both institutional ethics committee and signed informed consent was obtained from all patients.
Data collection
A baseline case report form was completed shortly before the BAL procedure.
Underlying diseases, fever, respiratory symptoms, response to any antimicrobial therapy, reason/s for the BAL procedure, and the presumed diagnosis based on the available evidence and clinical judgment at that time were recorded. Follow-up was conducted at days three and 30 after the BAL procedure.
Since one clinical episode could lead to several BAL procedures within a short period of time, we defined an exclusion strategy to avoid reporting multiple BAL procedures linked to a unique event as independent episodes. Any BAL performed within a four-week period of the previous procedure and yielding the same viral result was excluded from the analysis, but any BAL episode providing a positive result after a negative one was considered, independent of the time elapsed between the two episodes. 229E, NL63 and HKU1, and bocavirus were performed as previously described 9, 12, [14] [15] [16] . In 
Sample processing
RESULTS
Patients
Of 1242 
Microbiological analysis
Overall, 91 of 522 episodes (17.4%) were positive for at least one respiratory virus with a positivity rate that ranged between 12.3% and 31.6% according to the group studied (table 1) . These differences were not statistically significant. The distribution of the different viral genera and species recovered as well as their relative contribution and seasonality is shown in fig. 1 
Clinical features according to virological results
At the time of the BAL procedure, the physician in charge who was blinded to the Separately, we also analysed lung transplant recipients who represented the larger subgroup of patients enrolled. This analysis showed that the overall incidence of any respiratory symptoms (defined by the presence of at least one of the following: cough; sputum; dyspnoea; fever; or radiological infiltrate) among patients with a respiratory infection suspected before the BAL procedure was 73.7% compared to 38.6% of those without any previous suspicion (p<0.001). Importantly, in the group with a suspicion of respiratory infection, the respiratory viral detection rate was 24.4% compared to 13.8% in other cases (p=0.02). These two observations confirmed an association between the presence of symptoms and a positive viral detection.
DISCUSSION
This study shows that by using sensitive molecular assays, respiratory viruses are recovered in up to 17.4% of BAL specimens performed in a tertiary care hospital. Among all viruses screened, coronaviruses and rhinoviruses are the most frequent. A series of analyses of associated clinical conditions indubitably and consistently supported that these viral infections were associated with respiratory symptoms and complications. In particular, in the subgroup of lung transplant recipients, we were able to demonstrate that the detection of viral nucleic acid was significantly associated with respiratory symptoms and this corroborates its role in symptom production. The completeness of the molecular assays, the use of highly standardised lower respiratory specimens, and the fact that cases were not selected on predefined clinical conditions strengthen the accuracy of our findings.
Subjects enrolled were those that underwent a bronchoscopic procedure as a part of their clinical work-up to identify the cause of a potential respiratory infection. Although this approach limited the spectrum of respiratory diseases studied, this had the advantage to provide high quality lower respiratory tract specimens and to focus on hospitalized patients, those most at risk of complications. The viral detection rate was relatively similar across all subgroups studied. The temporal association between symptoms and the presence of a respiratory viral infection defined by a positive PCR assay was carefully assessed. Univariate analysis using the associated clinical, radiological or microbiological findings revealed a significant association between the presence of an acute respiratory disease and a positive PCR. In multivariate analysis, the non-response to antibiotherapy targeting a respiratory tract infection and the absence of radiological infiltrates were significantly associated with the presence of a positive viral detection. Analysis of the subgroup of lung transplant recipients in whom the BAL procedure is often performed as part of routine follow-up further confirmed the association between symptoms and viral infections. In a consistent manner, the viral infections concentrated clearly in lung transplant recipients in whom respiratory symptoms were exacerbated and a respiratory infection suspected. This is also consistent with previous studies 6, 18 .
By targeting 17 different viruses using similar sensitive nucleic detection assays applied on the most standardized lower respiratory tract specimens, and by avoiding the selection of cases for specific symptoms, our study is likely to provide a representative epidemiological pattern of lower respiratory tract viral infection in hospitalised adults. In this regard, the so-called "common cold" viruses, rhino-and coronavirus, are the most frequently encountered and represented 23% and 32% of our positive cases, respectively. This mirrors the epidemiology of the adult population living in the community. The ability of these viruses to cause lower respiratory tract diseases has been reported previously 6, 9, 13, 19, 20 and HRV is known to cause complications in asthma and chronic obstructive pulmonary disease patients as well as in lung transplant recipients. Coronavirus infections are also associated with lower respiratory diseases and pneumonia 10, 11, 19, [21] [22] [23] . Taken together, this highlights the significant impact of rhino-and coronaviruses compared to other more classical viruses such as influenza RSV and PIV, the latter three being the only target of many routine diagnostic procedures.
Some viruses such as HMpV, influenza C, enterovirus and PIV4 were very infrequent or absent in this adult population, perhaps reflecting a previous protective immunity or other seasonal aspects. Similarly, relatively few cases of bocavirus infections (3%) were diagnosed.
Most bocavirus studies have focused on children and only few reports have studied adults in whom the incidence seems significantly lower [24] [25] [26] . The use of new molecular tools targeting all respiratory viruses represents an opportunity to revisit the respective role of each of these agents. Nevertheless any conclusion drawn from this type of study needs to take into account the seasonality and the potential inability to detect new viral subtypes. Of note, our detection assays target viral RNA or DNA which does not prove per se the presence of fully competent and replicating virus. Although this could be considered as a limitation, it must be kept in mind that most of these viruses are not cultivable and that viral RNA is not equipped to survive in respiratory secretions without facing degradation or clearance by daily mucus production. Thus, a positive RT-PCR assay is most likely proof of an ongoing or a recent viral infection. Viral shedding has been shown to persist for days and even weeks in very young children and other immunocompromised patients 3, 16, 27 .
It is noteworthy that viruses such as influenza, or to a lesser extent RSV, for which an antiviral treatment might be available, accounted for only one-fifth of all positive cases in this adult population. This emphasizes the potential for therapy targeting other respiratory viruses which are still orphan of specific antiviral treatment.
Our study shows that respiratory viruses are detected in approximately one of five hospitalised adults presenting lower respiratory tract complications leading to a BAL procedure. When sensitive nucleic acid detection assays are used in this population, rhino-and coronaviruses are the leading agent detected. Our analysis supports a relationship between a positive viral detection and the presence of lower respiratory symptoms, as well as a poor response to antibiotherapy.
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